

NOVAGENIX

LABORATORIES

Annual Report 2025

Advancing Peptide Science for Global Health

Letter from the CEO

Dear Stakeholders,

2025 has been a landmark year for Novagenix Laboratories. Our commitment to advancing peptide science has yielded extraordinary results, both scientifically and commercially. Revenue grew 12% year-over-year to \$890 million, driven by strong demand for our metabolic health portfolio and successful expansion into Latin American markets.

Our flagship metabolic health program, NVG-101, advanced to Phase III clinical trials with compelling efficacy data. The SURMOUNT series of tirzepatide studies continues to validate the dual GLP-1/GIP agonist mechanism, with patients achieving 20-22% body weight reduction. Meanwhile, our triple agonist program NVG-415 — targeting GLP-1, GIP, and glucagon receptors simultaneously — demonstrated a remarkable 24-29% weight reduction in Phase II, positioning Novagenix at the frontier of next-generation obesity therapeutics.

We expanded our commercial footprint to 45+ countries, with particular momentum in Latin America where we established distribution partnerships in Bolivia, Colombia, and Brazil. Our GMP-certified manufacturing facilities maintained 100% compliance across all regulatory inspections, reinforcing our reputation for pharmaceutical excellence.

Research and development investment reached \$156 million — 18% of revenue — reflecting our conviction that today's research spending fuels tomorrow's breakthroughs. We filed 28 new patents and secured 5 additional regulatory approvals across multiple jurisdictions.

Our ESG commitments remain central to our identity. We advanced our Carbon Neutral 2030 roadmap, implemented green chemistry protocols that reduced solvent waste by 34%, and expanded our community health programs to serve over 15,000 patients in underserved regions.


Looking ahead to 2026, we anticipate Phase III readouts for NVG-101, continued enrollment in our retatrutide studies, and further geographic expansion. The global obesity therapeutics market exceeds \$100 billion, and Novagenix is uniquely positioned to capture significant market share through our differentiated peptide platform.

Thank you for your continued confidence in our mission.

Dr. Alexander Ivanov

Chief Executive Officer, Novagenix Laboratories

Financial Highlights FY2025







Quarterly Performance — Q4 2025

Revenue by Quarter		Operating Margins		Capital Allocation	
Q1	\$198M	Gross	72.4%	R&D	\$156M
Q2	\$212M	Operating	28.1%	CapEx	\$42M
Q3	\$235M	Net	7.5%	M&A	\$18M
Q4	\$245M	EBITDA	34.2%	Dividends	\$28M

Note: All financial figures are unaudited internal estimates. Novagenix Laboratories is a privately held company.

Innovation Pipeline

Our commitment to advancing peptide science through cutting-edge R&D.

CANDIDATE	THERAPEUTIC AREA	DISCOVERY	PRECLINICAL	PHASE I	PHASE II
NVG-101	Metabolic Health				
<p>Tirzepatide advanced formulation for sustained release and improved stability. Dual GLP-1/GIP agonist targeting obesity and type 2 diabetes. Phase III enrollment complete with 2,400+ patients across 12 countries.</p>					
NVG-415	Metabolic Health				
<p>Triple agonist (GLP-1/GIP/GCG) based on retatrutide. Phase II data shows 24-29% body weight reduction — the most potent weight loss peptide in clinical development. Preparing for Phase III initiation in Q3 2026.</p>					
NVG-204	Oncology				
<p>Peptide-drug conjugate targeting solid tumors. Novel linker technology enables selective payload delivery to cancer cells while sparing healthy tissue. Phase II trial ongoing in advanced breast cancer.</p>					
NVG-309	Neurology				
<p>Neuroprotective peptide for Alzheimer's disease. Crosses blood-brain barrier via proprietary transport mechanism. Phase I safety and tolerability study initiated in Q4 2025.</p>					

Key Publications

- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389:514-526.

Environment, Social & Governance

Environmental Stewardship

Carbon Neutral by 2030 — On track with 47% reduction achieved. Green chemistry protocols reduced solvent waste by 34%. Water-positive operations across all facilities. Zero-waste manufacturing initiative launched in 2024.

Social Responsibility

Community health programs served 15,000+ patients in underserved regions. Partnership with 12 academic institutions for peptide research training. 42% female representation in senior leadership. Employee wellness programs with 94% participation rate.

Governance Excellence

100% compliance across all GMP inspections. ISO 9001:2015 certified operations. Independent advisory board with quarterly oversight reviews. Transparent reporting standards aligned with global best practices.

Certifications & Compliance

GMP Certified

ISO 9001:2015

GLP Compliant

ICH Guidelines

Corporate Information

16th Floor, Moscow City Business Center
Presnenskaya Embankment
Moscow, Russia, 123317

Corporate Headquarters

Phone: +7 (495) 123-4567
Email: info@novagenixlaboratories.com
Web: novagenixlaboratories.com

Contact

Santa Cruz de la Sierra
Bolivia
Distribution & Commercial Operations

Latin America Office

Legal Disclaimer

This annual report contains forward-looking statements within the meaning of applicable securities legislation. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those anticipated. Novagenix Laboratories is a privately held company and is not required to make public filings. All financial figures presented herein are unaudited internal estimates provided for informational purposes only. This document is strictly confidential and intended solely for authorized stakeholders. Unauthorized reproduction, distribution, or disclosure of this material is prohibited. The clinical data referenced in this report relates to published studies by independent researchers and does not constitute a claim of direct involvement by Novagenix Laboratories in those specific clinical trials. All trademarks and trade names are the property of their respective owners.

© 2026 Novagenix Laboratories. All rights reserved.

novagenixlaboratories.com